Stock comparison
Halozyme Therapeutics
PTC Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
PTCT
PTC Therapeutics
Market cap
$5.93B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | PTCT | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 50C | HALO |
| Benjamin Graham | 73B | 12F | HALO |
| Philip Fisher | 55C | 54C | HALO |
| Peter Lynch | 43D | 43D | Tie |
| Joel Greenblatt | 30F | 2F | HALO |
| Charlie Munger | 70B | 42D | HALO |
| Terry Smith | 74B | 50C | HALO |
Side-by-side metrics
| Metric | HALO | PTCT |
|---|---|---|
| Market cap | $8.41B | $5.93B |
| P/E (TTM) | 24.0x | - |
| EV/EBIT | 10.2x | 6.4x |
| ROIC (TTM) | 23.65% | -2.38% |
| Gross margin | 81.24% | 77.84% |
| Net margin | 23.13% | -22.58% |
| Revenue CAGR 5y | 33.23% | 33.89% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Net margin23.13%vs -22.58%+198%
- ROIC (TTM)23.65%vs -2.38%+110%
- Market cap$8.41Bvs $5.93B+30%
PTCT leads on
- P/E (TTM)-vs 24.0x+176%
- Debt / Equity-vs 1.0x+143%
- EV/EBIT6.4xvs 10.2x+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.